Joint injuries trigger cellular senescence through DNA damage and oxidative stress, activating p53/p21 and p16INK4a pathways in cartilage and synovial cells. These senescent cells release inflammatory factors collectively called SASP (senescence-associated secretory phenotype), accelerating cartilage degradation and bone remodeling. Pre-clinical studies demonstrate that eliminating these senescent cells significantly reduces cartilage damage and associated pain. This finding represents a paradigm shift in understanding post-traumatic osteoarthritis, which affects younger adults differently than age-related arthritis through rapid, localized senescence rather than gradual wear. The therapeutic implications are substantial—senolytics could prevent the progression from acute injury to chronic arthritis, potentially sparing millions of young athletes and trauma patients from lifelong disability. Current senolytic drugs like dasatinib plus quercetin are already in clinical trials for age-related conditions, suggesting near-term translational potential. However, the challenge lies in precise timing and delivery—intervening too early might impair normal healing, while delayed treatment may miss the critical window. Advanced delivery systems using nanoparticles could enable targeted elimination of senescent cells while preserving healthy tissue regeneration.